Scientific deep-dive
SURPASS-PEDS: Tirzepatide for Children and Teens With Type 2 Diabetes
SURPASS-PEDS tested weekly tirzepatide in 99 youths aged 10 to under 18 with type 2 diabetes. HbA1c fell far more than on placebo at 30 weeks, but vomiting, abdominal pain and low blood sugar were more frequent, and long-term outcomes remain unknown.
Tirzepatide lowered blood sugar substantially more than placebo in children and teens with type 2 diabetes. In SURPASS-PEDS, a phase 3 trial of 99 participants aged 10 to under 18, HbA1c fell 2.23% on pooled 5 mg and 10 mg doses and rose 0.05% on placebo at 30 weeks, an estimated difference of -2.28% (95% CI -2.87 to -1.69).[1] The FDA label’s analysis of the same trial, which counts data regardless of adherence or rescue treatment, gives a smaller difference of -1.8%.[2] Both favor the drug. Neither can say yet whether it prevents the complications that make youth-onset diabetes so serious.
Why a trial in this age group matters
Type 2 diabetes that starts in childhood tends to be hard to control. In the TODAY trial, 51.7% of participants on metformin alone lost glycemic control over an average of 3.86 years.[4] When the same cohort was followed into young adulthood, at a mean age of 26.4 years, the cumulative incidence of diabetic kidney disease was 54.8%, and 60.1% had at least one complication.[5] Those figures explain why pediatric endocrinologists have wanted stronger options. They also set the bar: a better HbA1c is a surrogate, and SURPASS-PEDS was not designed to show fewer kidney, eye or nerve complications later in life.
Who was in SURPASS-PEDS
The double-blind period ran 30 weeks at 39 sites in eight countries, followed by a 22-week open-label extension in which everyone received tirzepatide.[1] Eli Lilly and Company funded the trial.[1] Participants were randomized 1:1:1 to tirzepatide 5 mg (n=32), tirzepatide 10 mg (n=33) or placebo (n=34), added to metformin (69%), basal insulin (8%) or both (23%).[1][2]
These were not newly diagnosed children. Mean age was about 15 years, mean diabetes duration 2.4 years, mean HbA1c 8.0%, mean weight 97 kg and mean BMI 35 kg/m²; 61% were female, 66% identified as Hispanic or Latino and 20% as American Indian or Alaska Native.[2] The registry entry required a body weight of at least 50 kg and a BMI above the 85th percentile, and excluded anyone with a history of diabetic ketoacidosis after diagnosis.[3] A smaller child, or a child with a ketoacidosis history, sits outside what the trial tested.
Two sets of numbers from one trial
Readers will see different results quoted for this trial, and the analysis method appears to be the reason. The label and the ClinicalTrials.gov entry report data collected regardless of whether participants stayed on the study drug or started rescue medication. On that basis, pooled tirzepatide changed HbA1c by -2.03% versus -0.23% on placebo, a difference of -1.80% (95% CI -2.35 to -1.25).[3] The label rounds this to -2.0%, -0.2% and -1.8%, and notes that week-30 HbA1c was missing for 6%, 9% and 18% of the placebo, 5 mg and 10 mg groups, filled in by multiple imputation.[2] This is what trialists usually call a treatment-regimen approach. The Lancet abstract reports the larger -2.28% figure and does not name its estimand, so the two should not be mixed in one comparison.[1]
| Measure | Placebo | 5 mg | 10 mg | Pooled |
|---|---|---|---|---|
| HbA1c change, label (%) | -0.2 | -1.9 | -2.2 | -2.0 |
| Difference from placebo, label (%) | n/a | -1.7 | -2.0 | -1.8 |
| HbA1c at or below 6.5%, label | 28% | 68% | 81% | 75% |
| Fasting glucose change, label (mg/dL) | -5 | -35 | -51 | -43 |
| BMI change, label | -0.5% | -6.9% | -10.8% | -8.8% |
| HbA1c change, Lancet abstract (%) | +0.05 | not in abstract | not in abstract | -2.23 |
| BMI reduction, Lancet abstract | 0.4% | 7.4% | 11.2% | not in abstract |
The label rows come from Table 9 of the prescribing information, and the Lancet rows from the published abstract.[1][2] The BMI drop is striking for a diabetes trial, and it appears dose-related within this small sample: -6.9% on 5 mg and -10.8% on 10 mg in the label analysis.[2] The abstract says glycemic efficacy was sustained up to 52 weeks but does not give a week-52 number, and that stretch was open-label.[1]
How it sits next to other youth diabetes drugs
No head-to-head trial in children compares these medicines. The table below sets separate placebo-controlled trials side by side, with different durations, background therapy and baseline HbA1c, so any gap between rows is indirect. Tirzepatide’s placebo-adjusted HbA1c reductions are numerically larger than those reported for liraglutide, weekly exenatide or empagliflozin.[2][6][8][9] Dulaglutide lowered HbA1c with no between-group BMI difference, while BMI fell in SURPASS-PEDS, a contrast that also crosses trials.[1][7]
| Drug and trial | Ages | Primary timepoint | HbA1c result | Weight or BMI in abstract |
|---|---|---|---|---|
| Tirzepatide 5 or 10 mg weekly, SURPASS-PEDS | 10 to under 18 | 30 weeks | -1.8% vs placebo (label); -2.28% (Lancet) | BMI down 7.4% on 5 mg and 11.2% on 10 mg vs 0.4% on placebo |
| Liraglutide up to 1.8 mg daily, Ellipse | 10 to under 17 | 26 weeks | -1.06 points vs placebo | Not stated |
| Dulaglutide 0.75 or 1.5 mg weekly, AWARD-PEDS | 10 to under 18 | 26 weeks | -0.6 and -0.9 points vs +0.6 on placebo | No between-group BMI difference |
| Exenatide 2 mg weekly | 10 to under 18 | 24 weeks | -0.85% vs placebo | -1.22 kg, not significant |
| Empagliflozin 10 or 25 mg, DINAMO | 10 to 17 | 26 weeks | -0.84% vs placebo | Not stated |
| Linagliptin 5 mg, DINAMO | 10 to 17 | 26 weeks | -0.34% vs placebo, not significant | Not stated |
Side effects parents should know about
Gastrointestinal events were the most common adverse effects in the trial, all mild to moderate, and they decreased over time; two participants (6%) on 5 mg stopped the drug because of an adverse event, and no deaths occurred.[1] The label is more specific, and it singles out three problems as more frequent in children than in adults:[2]
- Vomiting: 3% on placebo, 16% on 5 mg and 12% on 10 mg during the 30-week period.[2]
- Abdominal pain: 9% on placebo, 22% on 5 mg and 15% on 10 mg.[2]
- Low blood sugar: glucose below 54 mg/dL occurred in 30% and 27% of those on 5 mg and 10 mg with basal insulin, versus 10% on placebo, in groups of only 10 or 11 children. On metformin alone it was 9% and 9% versus 4%. No severe episodes were reported.[2]
During the double-blind period, 30 of 61 children on the drug (49%) developed anti-tirzepatide antibodies. Across the trial, hypersensitivity reactions occurred in 2 of 50 children with antibodies (4%) and none of 43 without, and the label reports no clinically significant effect of antibodies on the drug’s pharmacokinetics or effectiveness.[2] The boxed warning on thyroid C-cell tumors is not limited by age, and the drug is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.[2]
Two questions come up less often in summaries of this trial. On growth, the registry shows a height standard deviation score change of -0.100 on pooled tirzepatide and -0.11 on placebo at 30 weeks, which is reassuring as far as it goes, though 30 weeks cannot settle growth or adult height.[3] On mood, the registry lists one serious suicide attempt on placebo in the double-blind period and one on 10 mg in the open-label period, which is too few to interpret in either direction.[3] A propensity-matched TriNetX cohort of adolescents with overweight or obesity linked incretin drugs to fewer suicide-related events than lifestyle treatment (HR 0.74; 95% CI 0.57 to 0.95). The association was not significant in those with type 2 diabetes or in the comparison with metformin, and the authors warned of selection bias.[11]
For teens who could become pregnant
The Mounjaro label says the drug may reduce the efficacy of oral hormonal contraceptives. It advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. Non-oral hormonal methods should not be affected.[2] Since 61% of SURPASS-PEDS participants were female, this belongs in the first conversation with a prescriber.[2]
What the label allows, and what it does not
The August 2026 Mounjaro label indicates tirzepatide, with diet and exercise, to improve glycemic control in “adults and pediatric patients 10 years of age and older” with type 2 diabetes.[2] Dosing starts at 2.5 mg weekly and rises in 2.5 mg steps after at least 4 weeks on the current dose, with a pediatric maximum of 10 mg rather than the 15 mg allowed in adults.[2] The label does not recommend the KwikPen for self-administration by pediatric patients, and it says safety and effectiveness have not been established under age 10.[2]
The indication is diabetes, not weight. The August 2026 Zepbound label says safety and effectiveness “have not been established in pediatric patients.”[12] Two registered phase 3 trials in 12- to 17-year-olds address that question separately: SURMOUNT-ADOLESCENTS, whose registry lists primary completion in June 2026,[14] and SURMOUNT-ADOLESCENTS-2.[13] Families weighing an obesity drug can start with our review of GLP-1 evidence for teens 12 to 17, and those with younger children with our page on GLP-1 drugs under age 12.
Real-world data so far
One multicenter retrospective study has looked at 74 patients aged 21 or younger who were prescribed tirzepatide at three academic centers. Median age was 18.4 years, 86.5% had type 2 diabetes and 78.4% had already tried a GLP-1 drug. In those with diabetes, A1C fell from 8.0% to 7.2% (n=58) at a median of 102 days; BMI went from 42.7 to 42.0 kg/m² (n=69).[10] With no control group, older patients than the trial and heavy prior GLP-1 use, this describes practice and cannot estimate how well the drug works. The authors associated prior GLP-1 use and partial nonadherence with smaller A1C reductions.[10]
What SURPASS-PEDS leaves open
- Size. With 99 participants, the trial can detect a large HbA1c effect but cannot rule out uncommon harms.[1]
- Duration. Controlled data stop at 30 weeks, and the extension takes the treatment period to 52 weeks.[1] Youth-onset complications in TODAY built up over more than a decade.[5]
- Long-term use. The sources reviewed here do not report what happens when a child stops the drug, or how puberty and adult height look after years of treatment.
What to raise with your child’s care team
- Has metformin, with or without basal insulin, been tried at an adequate dose? SURPASS-PEDS added tirzepatide to those drugs.[1]
- If insulin is in the regimen, how will it be adjusted to limit low blood sugar, and who should the family call?[2]
- What is the plan for vomiting and fluid intake, and for checking growth and mood during treatment?
- Does your child weigh enough to resemble the trial population, which required at least 50 kg?[3]
Frequently Asked Questions
References
- 1.Hannon TS, Chao LC, Barrientos-Pérez M, Pamidipati KC, Landó LF, Lee CJ, Patel H, Bergman BK. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2025. PMID: 40975112.
- 2.Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information, revised August 2026. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 3.Eli Lilly and Company. A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (NCT05260021), posted results. ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT05260021
- 4.TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012. PMID: 22540912.
- 5.TODAY Study Group, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021. PMID: 34320286.
- 6.Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019. PMID: 31034184.
- 7.Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, et al. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022. PMID: 35658022.
- 8.Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, et al. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care. 2022. PMID: 35679098.
- 9.Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J, DINAMO Study Group. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023. PMID: 36738751.
- 10.Valdez Y, Segev N, Parimi N, Vegesna M, Brown EA, Samuels S, Van Name M, Shah AS, Wolf RM. Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis. J Pediatr Endocrinol Metab. 2026. PMID: 42576608.
- 11.Liu TH, Shen YL, Kuo TH, Wu JY, Lin CH, Lai CC. Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity. Diabetes Obes Metab. 2026. PMID: 42736027.
- 12.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, revised August 2026. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 13.Eli Lilly and Company. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) (NCT06439277). ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT06439277
- 14.Eli Lilly and Company. A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS) (NCT06075667). ClinicalTrials.gov. 2023. https://clinicaltrials.gov/study/NCT06075667
Related research
Lichen Sclerosus and Weight: Symptoms, Treatment, Obesity Links and Cancer Risk
Lichen sclerosus symptoms and treatment, and how it links to obesity and diabetes. Evidence on clobetasol and long-term steroid maintenance, urine trapped in buried skin, cancer risk and follow-up, and what weight loss and GLP-1 drugs can and cannot do.
11 min read
GLP-1 Drugs for Children Under 12: Trial Results, Prescribing Trends and FDA Limits
No GLP-1 drug is FDA-approved for weight loss in children under 12, but a 56-week trial found liraglutide lowered BMI in 6- to 11-year-olds and prescribing is rising. What parents should know about the evidence, side effects, label limits and open questions.
8 min read
Tirzepatide in Type 1 Diabetes: The Phase 2 Trial Results
The first placebo-controlled tirzepatide trial in type 1 diabetes found 8.7 kg more weight loss over 12 weeks and a 35.1% relative fall in insulin dose in 24 adults. Glucose findings were less clear, and larger phase 3 trials are registered.
8 min read
Mazdutide vs Dulaglutide in Type 2 Diabetes: The Nature Trials
In the phase 3 DREAMS-2 trial, mazdutide beat dulaglutide 1.5 mg on HbA1c and weight at 28 weeks in Chinese adults. Here is what the gap means, why the figures vary, and what the trials leave open on higher dulaglutide doses and heart outcomes.
8 min read
SURPASS-CVOT: Tirzepatide Cardiovascular Outcomes (2026)
SURPASS-CVOT (NEJM 2025) tested tirzepatide vs dulaglutide in 13,299 adults with type 2 diabetes and heart disease: MACE 12.2% vs 13.1%, HR 0.92 — non-inferior.
13 min read
ACHIEVE: Oral Orforglipron in Type 2 Diabetes (2026)
The oral orforglipron T2D phase 3 program (ACHIEVE, often searched as QWINT): HbA1c and weight results across five trials, the head-to-head win over oral semaglutide, and safety.
13 min read